Individual Investors Who Own 46% Along With Institutions Invested in Humacyte, Inc. (NASDAQ:HUMA) Saw Increase in Their Holdings Value Last Week

Simply Wall StDec 25, 2024 19:44

Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday

BenzingaDec 24, 2024 00:00

Humacyte Is Maintained at Buy by Benchmark

Dow JonesDec 23, 2024 22:31 · Ratings

Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $17

Futu NewsDec 23, 2024 20:31 · Ratings

Analysts Offer Insights on Healthcare Companies: Humacyte (HUMA) and Ligand Pharma (LGND)

TipRanksDec 23, 2024 19:50 · Ratings

Express News | Humacyte Inc : Benchmark Raises Target Price to $17 From $15

BreakingsDec 23, 2024 19:24